a61603

**A61603** is a potent and selective small molecule agonist of the **alpha-1A adrenergic receptor**. It shows much higher potency at alpha-1A sites compared to other alpha-1 receptor subtypes (alpha-1B, alpha-1D) and is used predominantly as a research tool to probe adrenergic function and regulation[1][3][5]. Its mechanism involves activation of **phosphoinositide hydrolysis** and the **ERK survival pathway** in cardiac myocytes, leading to cardioprotective effects such as reduced cardiac cell death, apoptosis, and fibrosis, especially in the context of doxorubicin-induced cardiomyopathy[3][6]. A61603 has been tested in animal models for heart failure, showing improvement in survival and cardiac function, often without significant changes in blood pressure at low doses[3][6]. It also impacts cardiac lipid and pyrimidine metabolism, reducing inflammation-associated metabolites in vivo[6]. Developed as a pharmacological probe and experimental therapeutic, A61603 is not an approved pharmaceutical but remains of interest in preclinical cardiac research.

Other names

N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide hydrobromide